The Biggest Shift in Women’s Hormone Health in Over Two Decades Just Happened

For more than 20 years, women sitting in their doctors’ offices were handed a verdict: hormone replacement therapy is dangerous. Stay away. The warning was stamped in black on every label, breast cancer, heart disease, dementia. Three of the most feared diagnoses in medicine, all attributed to the hormones that once made women feel like themselves.

On February 12, 2026, the FDA officially reversed that verdict.

The agency approved labeling changes to menopausal hormone therapy products, removing the “boxed warning” language related to cardiovascular disease, breast cancer, and probable dementia. This is not a minor tweak. A boxed warning, also called a black box warning, is the most serious safety warning the FDA applies to any drug. Stripping it signals a fundamental shift in how the agency reads the evidence.

This article is educational only and does not constitute medical advice. Every hormone therapy decision should be made with a qualified, licensed healthcare provider who knows your complete history.

That said, you deserve to understand exactly what changed, why it matters, and what the current science actually says. So let’s get into it.

What the FDA Actually Did (and Did Not Do)

The February 2026 announcement was the conclusion of a process that began in November 2025, when the Department of Health and Human Services and the FDA announced they were initiating the removal of boxed warnings from menopausal hormone therapy products. Twenty-nine drug companies submitted proposed labeling changes at the FDA’s request.

The first batch approved six products covered all four major categories of HRT for menopausal women:

• Systemic combination therapy (estrogen and progestogen together)
• Systemic estrogen-alone therapy
• Systemic progestogen-alone therapy (for women with a uterus who are also using systemic estrogen)
• Topical vaginal estrogen therapy

What was removed: Risk statements related to cardiovascular disease, breast cancer, and probable dementia from the formal boxed warning section.

What was NOT removed: The boxed warning for endometrial cancer on systemic estrogen-alone products in women who still have a uterus. That warning remains, and appropriately so, unopposed estrogen use in women with a uterus does carry an elevated endometrial cancer risk, which is why combination therapy exists.

What the new labeling adds: Guidance emphasizing the “timing hypothesis” that women who initiate HRT within 10 years of the onset of menopause, generally before age 60, see a meaningful reduction in all-cause mortality and fractures. This is now a labeled recommendation, not just academic commentary.

The updated prescribing information is publicly available through the FDA’s website, and the remaining 23 of the 29 companies who submitted proposed changes are expected to receive approval as the review process continues.

Why the Boxed Warning Existed in the First Place: The Women’s Health Initiative Story

To understand why this reversal matters so much, you have to understand how the original warning got there, and why it may have been one of the most consequential scientific miscommunications in the history of modern medicine.

The 2002 Women’s Health Initiative Study

In 2002, administrators of a federal research program called the Women’s Health Initiative (WHI) halted one arm of their study early. They announced that the risks of hormone replacement therapy outweighed the benefits, citing elevated risks of breast cancer, blood clots, and stroke in participants taking a combination of synthetic estrogen and progestin.

The media ran with it. Overnight, millions of women stopped taking HRT. Doctors stopped prescribing it. The FDA applied the black box warning that would define clinical practice for the next two decades.

What the headlines did not fully convey:

The study population was older than the typical HRT candidate. The average age of participants was 63 more than a decade past the average age of menopause onset, which is 51. These were not newly menopausal women. Many already had subclinical cardiovascular disease before the study began.

The drug used was not representative of modern HRT. The study used conjugated equine estrogen (Premarin) combined with medroxyprogesterone acetate (Provera) a synthetic progestin formulation that differs meaningfully from the bioidentical progesterone and transdermal estradiol used most commonly today.

The “26% increased risk” of breast cancer was statistically non-significant at the time of publication and was later shown to apply mainly to women who had been on synthetic hormones prior to entering the study. For women who had never used hormones before, the estrogen-only arm of the WHI actually showed a reduced risk of breast cancer.

The absolute numbers were buried. The relative risk increase in breast cancer translated to roughly 8 additional cases per 10,000 women per year. That is a meaningful number, but it looks very different from “26% increased risk” when you show it in absolute terms.

A landmark analysis published later estimated that between 2002 and 2012 — the decade when HRT prescriptions collapsed, as many as 91,000 postmenopausal women in the United States may have died prematurely from conditions that HRT might have helped prevent. That is the cost of getting the science wrong.

What Changed Between 2002 and 2026

It was not just one study that led to the 2026 reversal. It was the accumulation of more than two decades of better-designed research:

• The “timing hypothesis” now recognized as central to understanding HRT establishes that initiating therapy within 10 years of menopause onset, or before age 60, produces dramatically different outcomes than initiating it in older populations
• Multiple randomized trials confirmed that women in their 50s who used combination HRT or estrogen alone had up to a 30% lower risk of mortality compared to non-users
• Transdermal estradiol was shown to carry a significantly lower clot risk than oral estrogen because it bypasses first-pass liver metabolism
• Large observational studies and meta-analyses built a consistent picture of cardiovascular benefit, cognitive protection, and bone preservation for women who started HRT in the “window of opportunity” after menopause onset

In July 2025, the FDA convened an expert panel specifically to review the benefit-risk profile of menopausal hormone therapy. That panel’s conclusions, along with a comprehensive literature review and a public comment period, drove the regulatory action that followed.

What the Science Actually Says About HRT in 2026

Let’s go through the major systems that HRT affects and what the current evidence shows. This is educational information. Your licensed provider will determine whether this applies to your individual clinical picture.

Cardiovascular Disease

The original WHI raised alarms about cardiovascular risk. The current evidence tells a different story for appropriately timed therapy.

Women who initiate HRT within 10 years of menopause onset may reduce their risk of cardiovascular disease by as much as 50%. Estrogen plays a direct role in maintaining endothelial function, the health of the vessel lining, and in regulating lipid profiles. When estrogen declines, LDL rises, HDL falls, and arterial stiffness increases.

The timing hypothesis is critical here. Women who started HRT at age 63 in the WHI study, many of whom had pre-existing arterial disease,  experienced different outcomes than women in their early 50s who began therapy close to the menopausal transition. The cardiovascular benefit is a window, not a lifetime guarantee. This is part of why the FDA’s updated labeling now emphasizes starting within 10 years of onset or before age 60.

Transdermal estrogen delivery, patches, gels, creams applied to the skin, avoids the liver’s first-pass metabolism and carries a substantially lower thrombotic risk than oral estrogen. For most women today, transdermal is the preferred route of administration.

Breast Cancer

This is the fear that drove most women away from HRT after 2002, and it requires the most nuance.

The estrogen-only arm of the WHI actually found a reduced risk of breast cancer in women who had not used HRT previously. The elevated risk was associated primarily with the synthetic progestin (medroxyprogesterone acetate) used in the combination arm, and is not considered generalizable to bioidentical progesterone, which has a different receptor binding profile and a more favorable safety signal.

For most women without a personal history of hormone-receptor-positive breast cancer, and particularly those who begin HRT within 10 years of menopause onset, the FDA’s updated assessment is that the evidence does not support a boxed warning-level risk for breast cancer. The nuances of individual risk, family history, BRCA status, breast density, timing, formulation, are exactly why this conversation belongs between you and a knowledgeable provider.

Cognitive Health and Dementia

The original boxed warning cited “probable dementia” as a risk of HRT. That language has now been removed.

More recent research suggests the relationship between estrogen and cognitive function is timing-dependent and potentially protective. The “critical window” for cognitive benefit appears to be the same as for cardiovascular protection within 10 years of menopause onset. Studies have shown associations between early hormone therapy use and a reduced risk of Alzheimer’s disease, with some research suggesting up to a 35% reduction in risk.

The WHI memory sub study which initially raised concerns, studied women with an average age of 71. Applying those findings to newly menopausal women in their late 40s or 50s was, in retrospect, a significant methodological error.

Bone Health

This one has been consistently supported by evidence for decades, and it is not controversial. Estrogen is directly involved in bone remodeling. After menopause, bone loss accelerates significantly, and the 10-year fracture risk climbs in ways that are often underappreciated by both patients and providers.

HRT is FDA-approved for prevention of osteoporosis. Randomized studies show women using HRT can reduce bone fracture risk by 50 to 60%, one of the strongest effects of any available intervention for osteoporosis prevention.

Vasomotor Symptoms

Hot flashes. Night sweats. The symptoms that wake you up at 3am, soak your sheets, make you dread presentations, and quietly destroy your sleep quality for years. Up to 80% of women experience these symptoms, and for a significant subset they persist for 7 to 10 years or longer.

HRT remains the most effective treatment available for vasomotor symptoms. Nothing comes close. Non-hormonal options like certain antidepressants, gabapentin, and the newer neurokinin-3 receptor antagonists provide partial relief for some women, but the efficacy gap between those options and HRT is substantial.

Genitourinary Syndrome of Menopause (GSM)

Vaginal dryness, urinary urgency, pain with intercourse, recurrent urinary tract infections, the constellation of symptoms that falls under genitourinary syndrome of menopause affects a majority of postmenopausal women and, unlike vasomotor symptoms, often does not improve with time. It tends to worsen without treatment.

Low-dose vaginal estrogen used locally has minimal systemic absorption and has long been recognized even by more conservative practitioners as a low-risk intervention. The FDA’s removal of the boxed warning from topical vaginal estrogen therapy reflects the strong safety profile of this category.

Why So Few Women Have Been Using HRT — And What That Means

Here is a number that should concern anyone working in women’s health.

In 2020, approximately 41 million U.S. women were between the ages of 45 and 64. Only about 2 million women in that age range received an HRT prescription. That is less than 5% of the population that might potentially benefit.

The WHI fallout created a generation of providers who were afraid to prescribe hormone therapy and a generation of patients afraid to ask for it. The black box warning served as a formal institutional signal that this therapy was dangerous, even as the evidence was shifting. Primary care physicians who saw patients for 15 minutes could not be expected to fully contextualize the nuances of the timing hypothesis, formulation differences, and risk stratification in real time. So they defaulted to what the label said.

This matters because untreated menopause symptoms are not merely inconvenient. They affect sleep, which affects metabolic health, cardiovascular health, and mental health. Bone loss compounds silently for years. Cognitive resilience declines faster without estrogen’s neuroprotective effects. Cardiovascular risk accelerates. The women who lost access to effective therapy during the 20-year gap between the WHI and this FDA reversal paid a real health cost.

Who Is a Candidate for HRT? (And Who Might Not Be)

The FDA’s updated labeling and the current scientific consensus point toward the same framework for who benefits most. This is educational context, not a clinical recommendation. Always evaluate with a licensed provider.

Generally considered good candidates:

• Women experiencing significant menopausal symptoms, vasomotor symptoms, sleep disruption, cognitive changes, mood changes, genitourinary symptoms
• Women with early surgical menopause (premature ovarian insufficiency)
• Women in early perimenopause or within 10 years of their last period, generally under age 60
• Women with elevated osteoporosis risk who want a single intervention that addresses both symptoms and bone health

Situations requiring more individualized evaluation:

• Personal history of hormone-receptor-positive breast cancer
• Active or recent cardiovascular events (stroke, heart attack)
• History of blood clots (particularly with oral estrogen; transdermal may still be an option)
• Undiagnosed vaginal bleeding
• Active liver disease

The clinical nuance here is exactly why “personalized” and “functional medicine” approaches matter. A blanket yes or no on HRT is not good medicine. Your individual risk profile, symptom burden, hormone levels, medical history, and health goals all need to be factored in.

Bioidentical vs. Synthetic Hormones: What the FDA Change Does and Doesn’t Tell You

One question that comes up frequently is whether the FDA approval and labeling changes apply equally to compounded bioidentical hormone therapy and to FDA-approved pharmaceutical HRT.

The short answer: the FDA’s labeling changes apply to regulated pharmaceutical products, not to compounded preparations. However, the scientific data that drove the labeling changes including the favorable safety signals for bioidentical estradiol and progesterone, is relevant to how informed providers approach all hormone therapy today.

Bioidentical hormones, estradiol and progesterone that are structurally identical to what the human body produces, have a different risk profile than the synthetic conjugated equine estrogen and medroxyprogesterone acetate studied in the original WHI. Most of the fear generated by the WHI applied to those synthetic formulations. The evidence base for bioidentical hormone therapy, while not as large as for pharmaceutical HRT, has been growing steadily.

At 1st Optimal, we partner exclusively with PCAB-accredited compounding pharmacies to ensure that any compounded hormone therapy our members access meets the highest standards of purity, potency, and quality. This is non-negotiable for us. Patient safety and legal compliance are the foundation of everything we do.

How to Talk to Your Provider About HRT in 2026

The FDA’s action changes the starting point of this conversation. For years, many providers led with the boxed warning as a reason to avoid HRT entirely. That institutional backstop is gone for the major risk categories. What should replace it is a genuine, individualized risk-benefit conversation.

Here is what to bring to that conversation:

Know your symptom picture. Are you having vasomotor symptoms? What is your sleep quality like? Have you noticed cognitive changes, brain fog, word retrieval issues, memory lapses? Any genitourinary symptoms? The more clearly you can articulate what you are experiencing, the more productively you can discuss options.

Know your family history. Breast cancer history in first-degree relatives, cardiovascular disease history, and clotting disorders all affect the risk side of the equation.

Ask specifically about formulation and route. Transdermal estradiol and bioidentical progesterone have different safety profiles than oral synthetic formulations. The conversation about “HRT” is not one-size-fits-all.

Ask about the timing window. If you are in early perimenopause or recently postmenopausal, you are in the optimal window for initiating therapy. If your provider is not familiar with the timing hypothesis and the updated evidence base, that is worth noting.

Get baseline labs. A comprehensive hormone panel, estradiol, progesterone, FSH, LH, testosterone, DHEA-S, SHBG, along with a full metabolic panel and thyroid assessment gives you and your provider the data to make a genuinely personalized decision, not a statistical one.

What This Means If You Are in Perimenopause Right Now

Perimenopause, the transitional phase before your final period, which can last anywhere from 2 to 10 years, is increasingly recognized as a critical window for intervention. This is when estrogen levels begin fluctuating wildly and eventually declining. This is when symptoms often begin. And this is when the biology supports the strongest case for hormone therapy if you are a candidate.

The FDA’s updated labeling reinforces this. The labeled recommendation is to start within 10 years of menopause onset or before age 60. That recommendation is most naturally aligned with women who are in their mid-to-late 40s or early 50s, the perimenopausal years.

Many women in perimenopause are told their labs are “normal” because FSH or estradiol tested on a random day in a fluctuating cycle doesn’t always capture what is happening. Symptoms matter. The pattern of symptoms over time matters. The conversation with a knowledgeable provider matters.

The 1st Optimal Approach to Hormone Health

At 1st Optimal, hormone health is foundational, not an afterthought. The women who come to us are not looking for a one-size-fits-all prescription based on a 15-minute primary care visit. They are looking for providers who have read the same literature that drove the FDA’s 2026 decision, who understand the timing hypothesis, who know the difference between formulations, and who will treat them as individuals with a full clinical picture.

Our approach includes:

• Advanced hormone lab panels that go beyond the basics — including estradiol, progesterone, testosterone, DHEA-S, cortisol, thyroid markers, and metabolic indicators
• Individualized treatment protocols that consider your symptoms, your history, and your goals
• Continuous monitoring and adjustment — because hormone needs change over time
• Education-first care — you will understand what you are taking, why, and what we are watching for

If you are in perimenopause or postmenopause and you have been told that hormone therapy is not an option, or if you have never had a real conversation about it, the science has changed. The FDA has acknowledged that science. You deserve a provider who is working with current evidence.

How Estrogen Decline Affects the Whole Body: A Systems View

One of the most underappreciated aspects of menopause is how far-reaching the effects of estrogen loss actually are. Most women know about hot flashes. Fewer realize that estrogen has receptor sites in the brain, the heart, the liver, the gut, the skin, the joints, and the urinary tract. When estrogen drops, the effects are systemic, and the symptom picture often involves complaints that do not obviously connect to hormones.

Sleep Architecture

Estrogen and progesterone both influence sleep. Estrogen supports serotonin and other neurotransmitters that regulate sleep cycles. Progesterone has a direct sedating effect through GABA receptor activity. When both hormones decline in perimenopause and menopause, sleep architecture changes. Women typically see more fragmented sleep, reduced slow-wave sleep, and earlier morning awakening. Night sweats compound this by creating thermal disruption at night.

The downstream consequences of disrupted sleep, elevated cortisol, insulin resistance, impaired immune function, reduced cognitive recovery, weight gain, extend far beyond the bedroom.

Metabolic Health

Estrogen plays a direct role in insulin sensitivity. When estrogen levels drop, insulin resistance tends to increase, often accompanied by a shift in fat distribution from the hips and thighs (subcutaneous) to the abdomen (visceral). Visceral fat is metabolically active in ways that increase cardiovascular risk, inflammatory burden, and type 2 diabetes risk.

A 2025 research review examining 17 randomized controlled trials found that HRT significantly improves insulin sensitivity in women without diabetes. This metabolic protection is part of why the cardiovascular benefit of timely hormone therapy appears so meaningful.

Skin, Hair, and Connective Tissue

Estrogen regulates collagen synthesis, skin hydration, and tissue elasticity. Women commonly notice accelerated skin aging, thinning, and dryness in perimenopause changes that are real and biochemically driven, not merely cosmetic. Joint pain and stiffness also often appear in the perimenopausal transition, in part because estrogen has anti-inflammatory effects on joint tissue. The same estrogen receptors present in cartilage that are being lost during menopause can be supported through timely hormone therapy.

Gut Health and the Estrobolome

One underexplored connection: the gut microbiome plays a role in how estrogen is processed. A specific subset of gut bacteria called the estrobolome produce an enzyme (beta-glucuronidase) that helps regulate how much circulating estrogen is available. Disruptions in gut health can impair estrogen metabolism — which is one reason that functional medicine approaches to menopause look at gut health as part of the hormone picture, not separately from it.

What “Individualized” Hormone Therapy Actually Looks Like

The word “personalized” gets overused in healthcare marketing. In the context of hormone therapy, it has specific clinical meaning. Here is what individualized assessment looks like in practice.

Comprehensive Lab Testing

A baseline evaluation should include:

• Estradiol (E2): The primary form of circulating estrogen; levels fluctuate significantly during perimenopause and decline after menopause
• Progesterone: Often the first hormone to decline in perimenopause; low levels contribute to sleep disruption, anxiety, and cycle irregularities before periods even become irregular
• FSH (follicle-stimulating hormone): Elevates as the ovaries respond less reliably; elevated FSH confirms ovarian change but alone is not the full picture
• LH (luteinizing hormone): Works alongside FSH to signal ovarian function
• Total and free testosterone: Often overlooked in women, but testosterone significantly affects libido, energy, body composition, and cognitive sharpness in women and declines with age
• DHEA-S: A precursor hormone that converts to both estrogen and testosterone; produced primarily by the adrenal glands
• SHBG (sex hormone-binding globulin): Affects how much testosterone and estrogen is actually bioavailable versus bound and inactive; oral estrogen raises SHBG significantly, which can reduce free testosterone
• Thyroid panel (TSH, Free T3, Free T4): Thyroid dysfunction mimics and compounds many menopause symptoms; ruling it out is essential
• Cortisol: Chronic stress elevates cortisol and can suppress sex hormone production through a mechanism sometimes called “pregnenolone steal”
• Comprehensive metabolic panel and lipid panel: Baseline metabolic data is essential before and during hormone therapy

Symptom Mapping, Not Just Lab Values

Lab values exist within a clinical context. A woman with an estradiol level that looks borderline-low on a reference range but has severe vasomotor symptoms and sleep disruption is having a symptomatic menopause. Another woman with the same number might feel entirely fine. Symptoms and history matter at least as much as numbers.

The goal of individualized hormone therapy is to find the lowest effective dose that controls symptoms, maintains protective benefits, and is consistent with the woman’s personal risk profile and preferences. That is not a number to be found on a chart. It is a clinical conversation over time.

Monitoring and Adjustment

Hormone therapy is not a set-it-and-forget-it intervention. Needs change — sometimes because therapy needs titration, sometimes because life circumstances shift, sometimes simply because the transition through perimenopause continues. Follow-up labs and symptom check-ins at regular intervals are part of what real personalized care looks like.

HRT and Longevity: The Bigger Picture

The longevity medicine community has been paying close attention to the HRT research for years. The overlap between the “timing hypothesis” in hormone therapy and the mechanisms of aging is not coincidental.

Estrogen is broadly anti-inflammatory and has antioxidant properties. It supports mitochondrial function in cells. It plays a role in autophagy, the cellular cleanup process central to longevity biology. It maintains telomere length at a cellular level. These are not peripheral effects. They sit at the center of what drives biological aging in women.

The women who enter their 50s and 60s with well-maintained estrogen levels, whether naturally delayed menopause or through timely hormone therapy tend to show slower biological aging markers across multiple systems. The 50% reduction in cardiovascular disease risk, 35% reduction in Alzheimer’s risk, and 50 to 60% reduction in fracture risk associated with early hormone therapy are not just clinical endpoints. They are longevity metrics.

This does not mean hormone therapy is a cure for aging or appropriate for every woman. But in the conversation about how high-achieving women maintain their performance, cognitive sharpness, body composition, and vitality through the menopause transition and beyond, hormone therapy belongs at the center of that conversation, not at the margins of it.

Resources and Next Steps

The FDA’s updated prescribing information for menopausal hormone therapies with approved labeling changes is available directly on the FDA’s website under “Menopausal Hormone Therapies with Updated Prescribing Information.”

For women who want to dig deeper into the science:

• The Menopause Society (formerly NAMS) publishes evidence-based position statements on hormone therapy and menopause management
• The FDA’s November 2025 press release from HHS titled “HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy” provides the regulatory timeline

If you are ready to have a real conversation about your hormones based on advanced labs, your actual symptom picture, and current evidence rather than a two-decade-old warning label, we would like to meet you.

Start your 1st Optimal membership and get the hormone workup and individualized assessment you deserve.

The Bottom Line

Twenty years of women declining or being denied effective hormone therapy has had real consequences, on quality of life, on bone density, on cardiovascular health, on cognitive aging.

The FDA’s 2026 reversal does not change everything overnight. It will take time for clinical practice to catch up with updated labeling, for providers trained under the old framework to recalibrate, and for women who have been afraid of HRT for years to revisit the conversation.

But the institutional signal has changed. The evidence has always been more nuanced than the black box implied. Now the label reflects that.

If you have been white-knuckling through menopause symptoms without treatment because you were told the risks were too high — or if you simply never got a thorough conversation about your options — this is a good time to have that conversation with someone who is working with current evidence.

This content is for educational purposes only and does not constitute medical advice. Hormone replacement therapy requires evaluation by a qualified, licensed healthcare provider. Individual risk factors, medical history, and personal health goals must all be considered. Always consult with a licensed healthcare provider before beginning or changing any medication.

Ready to start your conversation? Book your lab panel with 1st Optimal and get a full hormone workup with a provider who understands the 2026 evidence.

Frequently Asked Questions: FDA HRT Label Change 2026

What did the FDA change about HRT labeling in 2026? The FDA approved the removal of boxed warning language related to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products. This affected all four categories of HRT: combination estrogen-progestogen, estrogen-alone, progestogen-alone (for women with a uterus on systemic estrogen), and topical vaginal estrogen.

Does this mean HRT is completely safe? No medication is without risk. The FDA’s action reflects that the evidence no longer supports applying the most severe warning category to these risk categories for most women who are appropriate candidates. Individual risk assessment with a knowledgeable provider remains essential.

Is the boxed warning for endometrial cancer also removed? No. The boxed warning for endometrial cancer on systemic estrogen-alone products in women with a uterus remains in place. This is because unopposed estrogen in women with an intact uterus does elevate endometrial cancer risk which is why progestogen is added in combination therapy.

What is the timing hypothesis in HRT? The timing hypothesis is the clinical framework that establishes women who start HRT within 10 years of menopause onset, or generally before age 60, experience different and more favorable outcomes than women who initiate HRT later. The cardiovascular, cognitive, and mortality benefits of HRT appear to be strongly dependent on this timing window.

Does the FDA change apply to bioidentical hormone therapy? The specific labeling changes apply to FDA-regulated pharmaceutical products. However, the science driving those changes including the favorable evidence for bioidentical estradiol and progesterone — is clinically relevant to how providers approach all hormone therapy.

Why was the boxed warning there for so long if the science was changing? The original warning was driven largely by the 2002 Women’s Health Initiative study, which has since been recognized as having significant design limitations including an older study population, synthetic hormone formulations no longer in common use, and risk calculations that conflated relative and absolute risk in ways that overstated the danger for most women. Regulatory processes move more slowly than the scientific literature.

Should I start HRT? That is a decision to make with a licensed, knowledgeable healthcare provider who knows your complete history. What the FDA’s 2026 action tells you is that the institutional barrier built by the old boxed warning is no longer there for cardiovascular disease, breast cancer, and probable dementia. The conversation with your provider can now start from an evidence-based place rather than from a decades-old warning.